Drug intelligence / Profile preview

KYLO-11

Development stage: Phase 2
Lead developer: Hygieia Pharma
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

KYLO-11 is an LPA-targeted small interfering RNA (siRNA) developed by Hygieia Pharmaceuticals and Kylonova (Xiamen) Biopharma co., LTD. It is designed to significantly reduce the expression of lipoprotein(a) (Lp(a)) levels. The drug is being investigated for the treatment of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD). Clinical trial results indicate that a single subcutaneous injection of KYLO-11 can achieve a greater than 95% Lp(a) reduction with a long-lasting effect, potentially for more than 12 months, and has exhibited a favorable safety profile. It leverages Hygieia's proprietary MVIP platform for efficient hepatic delivery of siRNA.

Targets

LPA (Lysophosphatidic acid)

Beyond the preview

Go deeper on KYLO-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KYLO-11.

Explore the full profile